Header Logo

Connection

NICOLA HANANIA to Pulmonary Disease, Chronic Obstructive

Back to Details
This is a "connection" page, showing publications NICOLA HANANIA has written about Pulmonary Disease, Chronic Obstructive.
NICOLA HANANIA
Connection Strength
27.689
Pulmonary Disease, Chronic Obstructive
  1. POINT: Should Triple Inhaled Therapy Be Considered in All Patients With Group E COPD? Yes. Chest. 2024 Jul; 166(1):12-17.
    View in: PubMed
    Score: 0.493
  2. Sex differences and determinants of anxiety symptoms in patients with COPD initiating pulmonary rehabilitation. Respir Med. 2024 06; 227:107633.
    View in: PubMed
    Score: 0.486
  3. Impact of antiviral therapy on short- and long-term outcomes of patients with chronic obstructive pulmonary disease after influenza infection. Influenza Other Respir Viruses. 2023 Dec; 17(12):e13231.
    View in: PubMed
    Score: 0.475
  4. Adding tiotropium or long-acting ?2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization. Allergy Asthma Proc. 2023 11 13; 44(6):413-421.
    View in: PubMed
    Score: 0.472
  5. Revisiting the Use of Antibiotics to Prevent COPD Exacerbation: Is Doxycycline the Answer? Am J Respir Crit Care Med. 2023 09 01; 208(5):509-511.
    View in: PubMed
    Score: 0.466
  6. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA. Int J Chron Obstruct Pulmon Dis. 2023; 18:407-418.
    View in: PubMed
    Score: 0.452
  7. Reducing the Risk of Mortality in Chronic Obstructive Pulmonary Disease With Pharmacotherapy: A Narrative Review. Mayo Clin Proc. 2023 02; 98(2):301-315.
    View in: PubMed
    Score: 0.447
  8. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction. Ann Allergy Asthma Immunol. 2023 02; 130(2):206-214.e2.
    View in: PubMed
    Score: 0.440
  9. When Asthma and Chronic Obstructive Pulmonary Disease Overlap; Current Knowledge and Unmet Needs. Immunol Allergy Clin North Am. 2022 08; 42(3):499-505.
    View in: PubMed
    Score: 0.432
  10. Pharmacologic Management Strategies of Asthma-Chronic Obstructive Pulmonary Disease Overlap. Immunol Allergy Clin North Am. 2022 08; 42(3):657-669.
    View in: PubMed
    Score: 0.432
  11. Phenotypes of Asthma-Chronic Obstructive Pulmonary Disease Overlap. Immunol Allergy Clin North Am. 2022 08; 42(3):645-655.
    View in: PubMed
    Score: 0.429
  12. Asthma-Chronic Obstructive Pulmonary Disease: An Update. Immunol Allergy Clin North Am. 2022 08; 42(3):xiii-xiv.
    View in: PubMed
    Score: 0.429
  13. The effectiveness of pulmonary rehabilitation on chronic obstructive pulmonary disease patients with concurrent presence of comorbid depression and anxiety. Respir Med. 2022 06; 197:106850.
    View in: PubMed
    Score: 0.423
  14. Predictors of premature discontinuation and prevalence of dropouts from a pulmonary rehabilitation program in patients with chronic obstructive pulmonary disease. Respir Med. 2022 03; 193:106742.
    View in: PubMed
    Score: 0.416
  15. Managing hospitalized patients with a COPD exacerbation: the role of hospitalists and the multidisciplinary team. Postgrad Med. 2022 Mar; 134(2):152-159.
    View in: PubMed
    Score: 0.415
  16. Treating COPD Patients with Inhaled Medications in the Era of COVID-19 and Beyond: Options and Rationales for Patients at Home. Int J Chron Obstruct Pulmon Dis. 2021; 16:2687-2695.
    View in: PubMed
    Score: 0.408
  17. Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials. Int J Chron Obstruct Pulmon Dis. 2021; 16:1925-1938.
    View in: PubMed
    Score: 0.400
  18. Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies. Int J Chron Obstruct Pulmon Dis. 2021; 16:865-875.
    View in: PubMed
    Score: 0.394
  19. Association of mild cognitive impairment and characteristic of COPD and overall health status in a cohort study. Expert Rev Respir Med. 2021 01; 15(1):153-159.
    View in: PubMed
    Score: 0.384
  20. Long-Term Benefits of Pulmonary Rehabilitation in Patients With COPD: A 2-Year Follow-Up Study. Chest. 2021 03; 159(3):967-974.
    View in: PubMed
    Score: 0.382
  21. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. Chest. 2021 03; 159(3):985-995.
    View in: PubMed
    Score: 0.381
  22. Response. Chest. 2019 12; 156(6):1276.
    View in: PubMed
    Score: 0.359
  23. Activity-related dyspnea in chronic obstructive pulmonary disease: physical and psychological consequences, unmet needs, and future directions. Int J Chron Obstruct Pulmon Dis. 2019; 14:1127-1138.
    View in: PubMed
    Score: 0.346
  24. Targeting IL-5 in COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:1045-1051.
    View in: PubMed
    Score: 0.346
  25. Validity and Responsiveness of the?Depression Anxiety Stress Scales-21?(DASS-21) in?COPD. Chest. 2019 06; 155(6):1166-1177.
    View in: PubMed
    Score: 0.337
  26. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:117-127.
    View in: PubMed
    Score: 0.337
  27. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019 04; 143(4):1629-1633.e2.
    View in: PubMed
    Score: 0.336
  28. COPD Management in the Primary Care Setting. J Fam Pract. 2018 10; 67(10 Suppl):S27-S32.
    View in: PubMed
    Score: 0.331
  29. Asthma COPD overlap: Impact of associated comorbidities. Pulm Pharmacol Ther. 2018 10; 52:27-31.
    View in: PubMed
    Score: 0.329
  30. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. Int J Chron Obstruct Pulmon Dis. 2018; 13:499-508.
    View in: PubMed
    Score: 0.317
  31. COPD in Primary Care: Key Considerations for Optimized Management: Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management. J Fam Pract. 2018 02; 67(2 Suppl):S11-S18.
    View in: PubMed
    Score: 0.316
  32. Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management. Cleve Clin J Med. 2018 Feb; 85(2 Suppl 1):S11-S18.
    View in: PubMed
    Score: 0.316
  33. Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts. J Am Med Dir Assoc. 2017 Dec 01; 18(12):1063-1068.
    View in: PubMed
    Score: 0.313
  34. Procalcitonin in Chronic Obstructive Pulmonary Disease Exacerbations: Is It Ready for Primetime Use? Ann Am Thorac Soc. 2017 12; 14(12):1757-1758.
    View in: PubMed
    Score: 0.313
  35. Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD. Expert Opin Emerg Drugs. 2017 09; 22(3):285-299.
    View in: PubMed
    Score: 0.307
  36. Effect of Yoga Breathing (Pranayama) on Exercise Tolerance in Patients with Chronic Obstructive Pulmonary Disease: A Randomized, Controlled Trial. J Altern Complement Med. 2017 Sep; 23(9):696-704.
    View in: PubMed
    Score: 0.305
  37. Safety of inhaled long-acting anti-muscarinic agents in COPD. Postgrad Med. 2017 Jun; 129(5):500-512.
    View in: PubMed
    Score: 0.300
  38. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension? Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017 05; 126:105-115.
    View in: PubMed
    Score: 0.297
  39. Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD. Expert Rev Respir Med. 2016 07; 10(7):767-80.
    View in: PubMed
    Score: 0.282
  40. The Responsiveness of the Anxiety Inventory for Respiratory Disease Scale Following Pulmonary Rehabilitation. Chest. 2016 07; 150(1):188-95.
    View in: PubMed
    Score: 0.277
  41. Hospital management of acute exacerbations of chronic obstructive pulmonary disease. J Hosp Med. 2015 May; 10(5):328-39.
    View in: PubMed
    Score: 0.260
  42. The asthma COPD overlap syndrome (ACOS). Curr Allergy Asthma Rep. 2015 Mar; 15(3):509.
    View in: PubMed
    Score: 0.258
  43. Evaluating the safety of COPD medications: an evidence-based review. Chest. 2013 Oct; 144(4):1357-1367.
    View in: PubMed
    Score: 0.234
  44. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Respir Med. 2014 Feb; 108(2):366-75.
    View in: PubMed
    Score: 0.234
  45. Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis. 2013; 8:117-25.
    View in: PubMed
    Score: 0.225
  46. Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Respir Med. 2012 Dec; 106 Suppl 2:S1-2.
    View in: PubMed
    Score: 0.221
  47. Effect of a primary care continuing education program on clinical practice of chronic obstructive pulmonary disease: translating theory into practice. Mayo Clin Proc. 2012 Sep; 87(9):862-70.
    View in: PubMed
    Score: 0.217
  48. The efficacy and safety of the novel long-acting ?2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012 Jul; 142(1):119-127.
    View in: PubMed
    Score: 0.215
  49. New bronchodilators. Curr Opin Pharmacol. 2012 Jun; 12(3):238-45.
    View in: PubMed
    Score: 0.211
  50. The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. Respir Med. 2012 Mar; 106(3):319-28.
    View in: PubMed
    Score: 0.207
  51. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012 Jan; 106(1):91-101.
    View in: PubMed
    Score: 0.205
  52. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. Respir Med. 2011 Oct; 105(10):1516-22.
    View in: PubMed
    Score: 0.204
  53. Bronchodilator reversibility in COPD. Chest. 2011 Oct; 140(4):1055-1063.
    View in: PubMed
    Score: 0.204
  54. The COPD Pipeline XII. COPD. 2011 Oct; 8(5):387-91.
    View in: PubMed
    Score: 0.203
  55. A unified front against COPD: clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society. Chest. 2011 Sep; 140(3):565-566.
    View in: PubMed
    Score: 0.203
  56. Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. COPD. 2011 Aug; 8(4):293-9.
    View in: PubMed
    Score: 0.202
  57. Safety of chronic obstructive pulmonary disease medications: a primary care perspective. Postgrad Med. 2011 May; 123(3):72-9.
    View in: PubMed
    Score: 0.198
  58. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res. 2011 Jan 11; 12:6.
    View in: PubMed
    Score: 0.194
  59. COPD in the elderly patient. Semin Respir Crit Care Med. 2010 Oct; 31(5):596-606.
    View in: PubMed
    Score: 0.191
  60. Budesonide/formoterol combination in COPD: a US perspective. Int J Chron Obstruct Pulmon Dis. 2010 Oct 05; 5:357-66.
    View in: PubMed
    Score: 0.190
  61. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011 Mar 01; 183(5):604-11.
    View in: PubMed
    Score: 0.190
  62. Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population. Int J Chron Obstruct Pulmon Dis. 2010 May 06; 5:125-32.
    View in: PubMed
    Score: 0.185
  63. Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). Respir Med. 2010 Aug; 104(8):1160-70.
    View in: PubMed
    Score: 0.183
  64. The safety and efficacy of arformoterol and formoterol in COPD. COPD. 2010 Feb; 7(1):17-31.
    View in: PubMed
    Score: 0.182
  65. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs. 2009 Jun 18; 69(9):1205-16.
    View in: PubMed
    Score: 0.174
  66. Evaluation of obstructive lung disease with vibration response imaging. J Asthma. 2008 Dec; 45(10):923-30.
    View in: PubMed
    Score: 0.168
  67. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Pulm Pharmacol Ther. 2008; 21(3):540-50.
    View in: PubMed
    Score: 0.157
  68. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc Am Thorac Soc. 2007 Oct 01; 4(7):526-34.
    View in: PubMed
    Score: 0.154
  69. Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes. Clin Ther. 2007 Oct; 29(10):2121-33.
    View in: PubMed
    Score: 0.154
  70. Update on the pharmacologic therapy for chronic obstructive pulmonary disease. Clin Chest Med. 2007 Sep; 28(3):589-607, vi-vii.
    View in: PubMed
    Score: 0.154
  71. One hundred years of chronic obstructive pulmonary disease (COPD). Respir Med. 2007 Jun; 101(6):1049-65.
    View in: PubMed
    Score: 0.149
  72. Can we predict depression in COPD? COPD. 2007 Mar; 4(1):3-4.
    View in: PubMed
    Score: 0.148
  73. The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPD. Int J Chron Obstruct Pulmon Dis. 2006; 1(4):345-54.
    View in: PubMed
    Score: 0.137
  74. Treatments for COPD. Respir Med. 2005 Dec; 99 Suppl B:S28-40.
    View in: PubMed
    Score: 0.135
  75. The challenge of differentiating asthma from chronic obstructive pulmonary disease. Manag Care. 2005 Jul; 14(7 Suppl Obstructie Lung):9-15; discussion 24-6.
    View in: PubMed
    Score: 0.132
  76. Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med. 2005 Mar; 11(2):129-34.
    View in: PubMed
    Score: 0.129
  77. The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm Pharmacol Ther. 2005; 18(1):19-22.
    View in: PubMed
    Score: 0.128
  78. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024 Jun 27; 390(24):2274-2283.
    View in: PubMed
    Score: 0.122
  79. Identification of sleep phenotypes in COPD using machine learning-based cluster analysis. Respir Med. 2024 06; 227:107641.
    View in: PubMed
    Score: 0.122
  80. Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020-2023. Lung. 2024 04; 202(2):119-125.
    View in: PubMed
    Score: 0.120
  81. Early Evidence of Chronic Obstructive Pulmonary Disease Obscured by Race-Specific Prediction Equations. Am J Respir Crit Care Med. 2024 01 01; 209(1):59-69.
    View in: PubMed
    Score: 0.119
  82. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003 Sep; 124(3):834-43.
    View in: PubMed
    Score: 0.116
  83. An Update on Outcomes for COPD Pharmacological Trials: A COPD Investigators Report - Reassessment of the 2008 American Thoracic Society/European Respiratory Society Statement on Outcomes for COPD Pharmacological Trials. Am J Respir Crit Care Med. 2023 08 15; 208(4):374-394.
    View in: PubMed
    Score: 0.116
  84. Novel Anti-Inflammatory Approaches to COPD. Int J Chron Obstruct Pulmon Dis. 2023; 18:1333-1352.
    View in: PubMed
    Score: 0.115
  85. Pharmacotherapies in Older Adults with COPD: Challenges and Opportunities. Drugs Aging. 2023 07; 40(7):605-619.
    View in: PubMed
    Score: 0.115
  86. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023 Jul 20; 389(3):205-214.
    View in: PubMed
    Score: 0.114
  87. Use of the Spirometric "Fixed-Ratio" Underdiagnoses COPD in African-Americans in a Longitudinal Cohort Study. J Gen Intern Med. 2023 10; 38(13):2988-2997.
    View in: PubMed
    Score: 0.113
  88. Prevalence of abnormal spirometry in individuals with a smoking history and no known obstructive lung disease. Respir Med. 2023 03; 208:107126.
    View in: PubMed
    Score: 0.112
  89. COPD: Providing the right treatment for the right patient at the right time. Respir Med. 2023 02; 207:107041.
    View in: PubMed
    Score: 0.111
  90. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. Respir Med. 2022 12; 205:107040.
    View in: PubMed
    Score: 0.110
  91. Clinical Markers Associated With Risk of Suicide or Drug Overdose Among Individuals With?Smoking Exposure: A Longitudinal Follow-up Study of the COPDGene Cohort. Chest. 2023 02; 163(2):292-302.
    View in: PubMed
    Score: 0.109
  92. Beta-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med. 2002 May 15; 165(10):1353-8.
    View in: PubMed
    Score: 0.106
  93. Depressive and anxiety symptoms in patients with COPD: A network analysis. Respir Med. 2022 07; 198:106865.
    View in: PubMed
    Score: 0.106
  94. Clinically Significant and Comorbid Anxiety and Depression Symptoms Predict Severe Respiratory Exacerbations in Smokers: A Post Hoc Analysis of the COPDGene and SPIROMICS Cohorts. Ann Am Thorac Soc. 2022 01; 19(1):143-146.
    View in: PubMed
    Score: 0.104
  95. Impact of influenza infection on the short- and long-term health of patients with chronic obstructive pulmonary disease. J Med Econ. 2022 Jan-Dec; 25(1):930-939.
    View in: PubMed
    Score: 0.104
  96. Association of Systemic Inflammation with Depressive Symptoms in Individuals with COPD. Int J Chron Obstruct Pulmon Dis. 2021; 16:2515-2522.
    View in: PubMed
    Score: 0.101
  97. Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. Respir Med. 2021 01; 176:106278.
    View in: PubMed
    Score: 0.096
  98. Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. Thorax. 2020 09; 75(9):735-743.
    View in: PubMed
    Score: 0.094
  99. The Hospital Readmissions Reduction Program and Readmissions for Chronic Obstructive Pulmonary Disease, 2006-2015. Ann Am Thorac Soc. 2020 04; 17(4):450-456.
    View in: PubMed
    Score: 0.092
  100. Precision medicine and treatable traits in chronic airway diseases - where do we stand? Curr Opin Pulm Med. 2020 01; 26(1):33-39.
    View in: PubMed
    Score: 0.090
  101. Clinical Epidemiology of COPD: Insights From 10 Years of the COPDGene Study. Chest. 2019 08; 156(2):228-238.
    View in: PubMed
    Score: 0.087
  102. Symptoms of anxiety and depression and use of anxiolytic-hypnotics and antidepressants in current and former smokers with and without COPD - A cross sectional analysis of the COPDGene cohort. J Psychosom Res. 2019 03; 118:18-26.
    View in: PubMed
    Score: 0.084
  103. New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology. Int J Chron Obstruct Pulmon Dis. 2018; 13:2805-2819.
    View in: PubMed
    Score: 0.082
  104. Clinical Approach to the Therapy of Asthma-COPD Overlap. Chest. 2019 01; 155(1):168-177.
    View in: PubMed
    Score: 0.082
  105. Results of a Pulmonologist Survey Regarding Knowledge and Practices With Inhalation Devices for COPD. Respir Care. 2018 07; 63(7):840-848.
    View in: PubMed
    Score: 0.080
  106. Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices. Respir Care. 2018 07; 63(7):833-839.
    View in: PubMed
    Score: 0.080
  107. Obesity modulates diaphragm curvature in subjects with and without COPD. Am J Physiol Regul Integr Comp Physiol. 2017 Nov 01; 313(5):R620-R629.
    View in: PubMed
    Score: 0.077
  108. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. COPD. 2017 Oct; 14(5):552-563.
    View in: PubMed
    Score: 0.076
  109. Trends in 30-day readmission rates after COPD hospitalization, 2006-2012. Respir Med. 2017 Sep; 130:92-97.
    View in: PubMed
    Score: 0.076
  110. The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort. J Am Med Dir Assoc. 2017 Nov 01; 18(11):955-959.e6.
    View in: PubMed
    Score: 0.076
  111. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017 02 01; 195(3):324-330.
    View in: PubMed
    Score: 0.074
  112. Obesity Is Associated With Increased Morbidity in Moderate to Severe COPD. Chest. 2017 Jan; 151(1):68-77.
    View in: PubMed
    Score: 0.072
  113. Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. PLoS Genet. 2016 Aug; 12(8):e1006011.
    View in: PubMed
    Score: 0.071
  114. Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2016 07; 13(7):1016-25.
    View in: PubMed
    Score: 0.071
  115. Long-term Course of Depression Trajectories in Patients With COPD: A 3-Year Follow-up Analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Cohort. Chest. 2016 Apr; 149(4):916-26.
    View in: PubMed
    Score: 0.068
  116. Age-Related Differences in Health-Related Quality of Life in COPD: An Analysis of the COPDGene and SPIROMICS Cohorts. Chest. 2016 Apr; 149(4):927-35.
    View in: PubMed
    Score: 0.068
  117. Differences between absolute and predicted values of forced expiratory volumes to classify ventilatory impairment in chronic obstructive pulmonary disease. Respir Med. 2016 Feb; 111:30-8.
    View in: PubMed
    Score: 0.068
  118. A review of the most common patient-reported outcomes in COPD--revisiting current knowledge and estimating future challenges. Int J Chron Obstruct Pulmon Dis. 2015; 10:725-38.
    View in: PubMed
    Score: 0.065
  119. Executive summary: prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015 Apr; 147(4):883-893.
    View in: PubMed
    Score: 0.065
  120. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015 Apr; 147(4):894-942.
    View in: PubMed
    Score: 0.065
  121. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015 Jan; 12(1):27-34.
    View in: PubMed
    Score: 0.064
  122. A simplified score to quantify comorbidity in COPD. PLoS One. 2014; 9(12):e114438.
    View in: PubMed
    Score: 0.064
  123. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014 Dec; 146(6):1531-1542.
    View in: PubMed
    Score: 0.063
  124. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. Respir Med. 2014 Sep; 108(9):1310-20.
    View in: PubMed
    Score: 0.062
  125. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013 May; 1(3):210-23.
    View in: PubMed
    Score: 0.057
  126. Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives. COPD. 2013 Aug; 10(4):482-92.
    View in: PubMed
    Score: 0.057
  127. Comparative effectiveness of noninvasive ventilation vs invasive mechanical ventilation in chronic obstructive pulmonary disease patients with acute respiratory failure. J Hosp Med. 2013 Apr; 8(4):165-72.
    View in: PubMed
    Score: 0.056
  128. Racial differences in CT phenotypes in COPD. COPD. 2013 Feb; 10(1):20-7.
    View in: PubMed
    Score: 0.056
  129. The safety of long-acting ?2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013; 8:53-64.
    View in: PubMed
    Score: 0.056
  130. Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. Health Qual Life Outcomes. 2012 Aug 23; 10:100.
    View in: PubMed
    Score: 0.054
  131. A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD. 2012 Apr; 9(2):151-9.
    View in: PubMed
    Score: 0.053
  132. Glucose and pyruvate metabolism in severe chronic obstructive pulmonary disease. J Appl Physiol (1985). 2012 Jan; 112(1):42-7.
    View in: PubMed
    Score: 0.051
  133. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011 Aug 02; 155(3):179-91.
    View in: PubMed
    Score: 0.050
  134. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology. 2011 Oct; 261(1):274-82.
    View in: PubMed
    Score: 0.050
  135. Gender differences of airway dimensions in anatomically matched sites on CT in smokers. COPD. 2011 Aug; 8(4):285-92.
    View in: PubMed
    Score: 0.050
  136. Racial differences in quality of life in patients with COPD. Chest. 2011 Nov; 140(5):1169-1176.
    View in: PubMed
    Score: 0.050
  137. Measuring the impact of a live, case-based, multiformat, interactive continuing medical education program on improving clinician knowledge and competency in evidence-based COPD care. Int J Chron Obstruct Pulmon Dis. 2011; 6:297-307.
    View in: PubMed
    Score: 0.050
  138. Resting energy expenditure and protein turnover are increased in patients with severe chronic obstructive pulmonary disease. Metabolism. 2011 Oct; 60(10):1449-55.
    View in: PubMed
    Score: 0.050
  139. Prevalence of airway obstruction assessed by lung function questionnaire. Mayo Clin Proc. 2011 May; 86(5):375-81.
    View in: PubMed
    Score: 0.050
  140. Arformoterol tartrate in the treatment of COPD. Expert Rev Respir Med. 2010 Apr; 4(2):155-62.
    View in: PubMed
    Score: 0.046
  141. Development of the Lung Function Questionnaire (LFQ) to identify airflow obstruction. Int J Chron Obstruct Pulmon Dis. 2010 Feb 18; 5:1-10.
    View in: PubMed
    Score: 0.046
  142. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. Adv Ther. 2009 Nov; 26(11):1024-34.
    View in: PubMed
    Score: 0.045
  143. The aging immune system and its relationship to the development of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009 Dec 01; 6(7):573-80.
    View in: PubMed
    Score: 0.045
  144. Development and validation of the Chronic Obstructive Pulmonary Disease Assessment Questionnaire (COPD-AQ). Prim Care Respir J. 2009 Sep; 18(3):198-207.
    View in: PubMed
    Score: 0.044
  145. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008 Oct; 134(4 Suppl):43S-56S.
    View in: PubMed
    Score: 0.041
  146. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Respir Dis. 2008 Aug; 2(4):199-208.
    View in: PubMed
    Score: 0.041
  147. It's about time--directing our attention toward modifying the course of COPD. Respir Med. 2008 Jun; 102 Suppl 1:S37-48.
    View in: PubMed
    Score: 0.040
  148. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis. 2008 Apr; 2(2):37-48.
    View in: PubMed
    Score: 0.040
  149. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD. 2008 Feb; 5(1):25-34.
    View in: PubMed
    Score: 0.040
  150. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. Clin Ther. 2008; 30 Spec No:989-1002.
    View in: PubMed
    Score: 0.039
  151. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Feb; 29(2):261-78.
    View in: PubMed
    Score: 0.037
  152. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther. 2005 May; 27(5):531-42.
    View in: PubMed
    Score: 0.033
  153. Bayesian inference of networks across multiple sample groups and data types. Biostatistics. 2020 07 01; 21(3):561-576.
    View in: PubMed
    Score: 0.023
  154. Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler. J Aerosol Med Pulm Drug Deliv. 2017 Aug; 30(4):256-266.
    View in: PubMed
    Score: 0.018
  155. An Official American Thoracic Society Workshop Report: Evaluation and Management of Asthma in the Elderly. Ann Am Thorac Soc. 2016 11; 13(11):2064-2077.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.